New treatments for type 2 diabetes--the DPP4 inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18632049.
- Also identified by DOI 10.1016/j.pcd.2007.10.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sitagliptin (brand name Januvia) the first of a new class of oral agents, the DPP4 inhibitors, which lower blood glucose in type 2 diabetes has recently been launched in UK. Another DPP4 inhibitor vildagliptin is due to be launched soon, and there are several others in the pipeline. This article gives an overview of this new class of medications.
Medical subject headings
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Pyrazines
- Triazoles